Life Sciences

  • April 27, 2026

    McCarter & English Plans New Waterfront Home In Boston

    New Jersey-based McCarter & English LLP has chosen a new home for its Boston office, opting for a location in the middle of the city's downtown waterfront district, the firm has announced.

  • April 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week tackled a fresh mix of deal litigation, procedural disputes and fiduciary duty claims, with several rulings and filings underscoring the court's continued focus on contractual precision, forum enforcement and the limits of stockholder challenges.

  • April 27, 2026

    What To Watch As Justices Take On 'Skinny Label' Case

    The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the drug industry that could shape patent disputes more broadly and other legal areas. Here's what to watch for.

  • April 27, 2026

    Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy

    Eli Lilly and Co. said Monday it will acquire privately held Ajax Therapeutics in a deal worth up to $2.3 billion, as the drugmaker looks to expand its pipeline of treatments for blood cancers.

  • April 27, 2026

    US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal

    Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.

  • April 24, 2026

    Up Last At High Court: TPS, Geofence, Skinny Labels

    The U.S. Supreme Court will close out its oral argument portion of the 2025 October term by hearing a panoply of disputes over the constitutionality of geofence warrants, the existence of aiding and abetting torture claims, and the rescission of temporary protected status for hundreds of thousands of immigrants.

  • April 24, 2026

    Natera Tells Justices CareDx Made Up Circ. Split In Petition

    Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."

  • April 24, 2026

    NY Court Pauses $100M Saudi Arabia Pharma Award Suit

    A New York federal judge has paused litigation filed by a Qatari pharmaceutical distributor and its chairman aimed at enforcing a nearly $100 million arbitral award against Saudi Arabia while a hearing is conducted in the kingdom's set-aside petition in England next week.

  • April 24, 2026

    What's At Stake As High Court Hears Roundup Appeal

    With a $7.25 billion deal potentially at stake, Monsanto heads to the U.S. Supreme Court on Monday in its closely watched appeal of a $1.25 million jury verdict awarded to a Missouri man who claimed that Roundup weed killer caused his cancer.

  • April 24, 2026

    Danaher Execs Face Investor Suit Over Post-COVID Outlook

    Danaher Corp. executives are facing a proposed securities class action in Delaware federal court alleging they profited while misleading stockholders about the slowing sales of its diagnostics and bioprocessing products.

  • April 24, 2026

    Merck's $6.7B Terns Deal Clears Regulatory Hurdle

    Merck has cleared a key regulatory hurdle in its plan to acquire clinical stage oncology company Terns Pharmaceuticals Inc. for $6.7 billion, the pharmaceutical giant said Friday. 

  • April 24, 2026

    Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial

    Pfizer and Israeli generic-drug maker Dexcel on Friday agreed to drop a case Pfizer brought to block Dexcel from creating a generic version of the heart medication Vyndamax.

  • April 24, 2026

    Biotechs Clash Over Cancer Drug Discovery In Chancery

    AnaptysBio and Tesaro, alongside Tesaro parent GlaxoSmithKline LLC, sparred Friday in the Delaware Chancery Court over the scope of discovery in the biotechnology firms' contract fight regarding cancer drug Jemperli, with each side accusing the other of trying to tilt the evidentiary record ahead of a fast-approaching trial in July.

  • April 24, 2026

    Taxation With Representation: Gibson Dunn, Paul Weiss

    In this week's Taxation With Representation, Elon Musk's SpaceX strikes a deal with Cursor that could lead to an acquisition of the artificial intelligence startup, building products distributor QXO Inc. buys TopBuild Corp., and Eli Lilly & Co. acquires clinical-stage biotechnology company Kelonia Therapeutics.

  • April 23, 2026

    Latest Squires Order Grants 5 IPRs, Denies 4 On The Merits

    U.S. Patent and Trademark Office Director John Squires granted five America Invents Act patent challenges and denied four others in his latest bulk order making institution decisions with little commentary.

  • April 23, 2026

    Full Fed. Circ. Urged To Rethink Corcept Patent Loss

    Corcept Therapeutics Inc. wants the Federal Circuit to rethink a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying the panel improperly relied on a ruling from a 2022 case.

  • April 23, 2026

    FTC Cuts Deal To End Anesthesia Group Rollup Case

    The Federal Trade Commission reached an agreement Thursday to settle its case accusing U.S. Anesthesia Partners Inc. of monopolizing the Texas anesthesia services market by purchasing most of the competing anesthesia practices in the state.

  • April 23, 2026

    Pa. County Joins Insulin-Pricing Suit Blitz Against CVS, PBMs

    Chester County, Pennsylvania, filed its own suit in a sprawling multidistrict litigation against CVS and multiple pharmacy benefit managers and drug companies, claiming the entities worked together to inflate the price of insulin.

  • April 23, 2026

    Kirkland To Add Tenn. SG Behind Skrmetti Supreme Court Win

    The Tennessee solicitor general, who successfully defended the state's ban on some gender-affirming care for minors before the U.S. Supreme Court, will join the Nashville office of Kirkland & Ellis, the firm announced Thursday. 

  • April 23, 2026

    Firm Seeking Philly Zantac Judge's Recusal Appeals Refusal

    A plaintiff represented by Keller Postman LLC has asked the Pennsylvania Superior Court to weigh in on a Philadelphia judge's refusal to recuse himself from overseeing mass tort litigation against GlaxoSmithKline over Zantac's alleged cancer risks.

  • April 23, 2026

    ITC Investigating Chinese Biopharma Chemicals Over Pricing

    The U.S. International Trade Commission is looking into whether Chinese imports of two chemicals used in biopharma manufacturing that are allegedly being sold at unfair prices are harming U.S. domestic industry, it said in a notice published Thursday.

  • April 23, 2026

    DOJ Says Medical Pot Shift Shouldn't Affect Gun Rights Case

    Despite an order from the U.S. Department of Justice loosening federal restrictions on medical marijuana, the Trump administration signaled Thursday that it does not intend for the changes to cannabis regulation to apply retroactively.

  • April 23, 2026

    Trulieve Says Infringement Suit Doesn't Actually State A Claim

    Cannabis company Trulieve Inc. has said a rival company's complaint against it lacks any factual basis to support the allegation Trulieve infringed the rival's patents, urging a Florida federal court to throw out the suit.

  • April 23, 2026

    DOJ Final Order Loosens Rules For State-Legal Medical Pot

    The U.S. Department of Justice published a final order Thursday loosening federal restrictions on medical marijuana products that fall within the ambit of state-regulated programs or have approval from the U.S. Food and Drug Administration.

  • April 22, 2026

    Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid

    The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage biotechnology company Regenxbio Inc.

Expert Analysis

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.